Your session is about to expire
← Back to Search
Other
PrimeC for ALS (PARADIGM Trial)
Phase 2
Waitlist Available
Research Sponsored by NeuroSense Therapeutics Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Item 3 (swallowing) in ALSFRS-R ≥ 3
Upright slow vital capacity (SVC) ≥ 60% of predicted for age, height, weight and sex at screening according to the GLI-2012
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
PARADIGM Trial Summary
This trialwill study a drug for ALS in 69 people. They'll take it twice a day for 6 months and have safety and efficacy tests over that time. 12 more months of testing to follow.
Who is the study for?
This trial is for adults aged 18-75 with ALS, who can understand and agree to the study terms. They must have an ALSFRS-R score ≥25, stable swallowing ability, a BMI between 18-30, disease duration less than 30 months from first symptom, and meet specific breathing capacity criteria. Women must meet reproductive standards. Exclusions include severe diabetes, heart issues, renal impairment, cognitive problems or other significant illnesses.Check my eligibility
What is being tested?
The study tests PrimeC against a placebo in people with ALS. Participants are randomly assigned in a 2:1 ratio to either receive PrimeC or placebo twice daily for six months while continuing standard treatments like riluzole and edaravone. After six months of treatment, all participants will receive PrimeC during a year-long open label extension phase.See study design
What are the potential side effects?
While the side effects of PrimeC are not detailed here specifically since it's under investigation; generally such trials monitor for adverse reactions including digestive issues, allergic responses to medication components if known allergies exist and potential interactions with existing medications.
PARADIGM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can swallow without significant difficulty.
Select...
My lung function test shows I'm at least 60% of the expected value for my age, height, weight, and sex.
Select...
I have been diagnosed with ALS.
Select...
I meet the specific reproductive health requirements.
Select...
I am between 18 and 75 years old.
PARADIGM Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence and severity of treatment-emergent adverse events (TEAEs)
Number of patients who discontinued treatment prematurely due to adverse events
Number of patients with clinically significant abnormal laboratory values
+3 moreSecondary outcome measures
Change from baseline to 6 months in ALS functional rating scale - revised (ALSFRS-R)
Change from baseline to 6 months in PROMIS-10 quality of life questionnaire
Change from baseline to 6 months in quality of life ALSSQOL-SF
+4 moreOther outcome measures
Change from baseline to 6 months in Patient-ranked order of function (PROOF)
Change from baseline to 6 months in the following serum biomarkers: serum ferritin, transferrin, iron, neurofilaments and exosomal LC3, Dicer, and other biomarkers evaluating the effect of PrimeC on pathophysiological mechanisms in ALS
Effect of PrimeC versus placebo on the time to reach advanced disease stages (King's/MiToS)
PARADIGM Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: PrimeCActive Control1 Intervention
2 tablets of PrimeC administered twice daily (4 tablets a day), at a daily dose of 1496 mg
Group II: PlaceboPlacebo Group1 Intervention
2 tablets of Placebo administered twice daily (4 tablets a day). Placebo tablets are matched in size, color and taste.
Find a Location
Who is running the clinical trial?
NeuroSense Therapeutics Ltd.Lead Sponsor
5 Previous Clinical Trials
77 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your ALSFRS-R score at screening needs to be 25 or higher.My kidney function is impaired with high creatinine levels.I can swallow without significant difficulty.I use a tracheostomy or feeding tube.I am a poor metabolizer for certain medications due to my CYP2C9 status.Your ALS symptoms have been getting worse by 0.3 points or more each month since they started.Your body mass index (BMI) is between 18 and 30.I have difficulty with memory or thinking clearly.I have a serious stomach issue, like an ulcer, tumor, or I've had weight loss surgery.I have a serious heart, lung, muscle, or mental health condition.I have heart problems like heart failure, heart attack, high blood pressure, or irregular heartbeat.My blood pressure and heart function meet the study's requirements.My lung function test shows I'm at least 60% of the expected value for my age, height, weight, and sex.I am currently pregnant, breastfeeding, or planning to become pregnant.I have been diagnosed with ALS.I meet the specific reproductive health requirements.I have a history of heart rhythm issues or epilepsy.I have been on stable medication for at least 60 days before joining.My diabetes is hard to control or fluctuates a lot.I am between 18 and 75 years old.I cannot take certain medications due to adverse reactions.I understand what participating in this study involves.I regularly use aspirin or NSAIDs.You are prone to getting tendinitis.I have a condition or situation that makes it hard for me to join the study.I use daily medication for my COPD or asthma.My muscle weakness started less than 30 months ago.
Research Study Groups:
This trial has the following groups:- Group 1: PrimeC
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger